Indivior Pharmaceuticals
INDV
99 hedge funds and large institutions have $1.22B invested in Indivior Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 28 increasing their positions, 30 reducing their positions, and 14 closing their positions.
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
4% more funds holding
Funds holding: 95 → 99 (+4)
9% more call options, than puts
Call options by funds: $8.18M | Put options by funds: $7.51M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 30
1.22% less ownership
Funds ownership: 49.55% → 48.33% (-1.2%)
64% less capital invested
Capital invested by funds: $3.4B → $1.22B (-$2.19B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$47.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$28.5M |
| 3 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
+$20.6M |
| 4 |
Legal & General Group
London,
United Kingdom
|
+$16.6M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$7.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$783M |
| 2 |
Goldman Sachs
New York
|
-$58.9M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$34.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$22.4M |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$17.2M |
INDV Hedge Fund Activity: Q2 2024 in Review
99 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q2 2024, worth a combined $1.22B — down 64% from $3.4B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new INDV positions and 14 closed out — a net gain of 5 holders — while 28 added to existing stakes and 30 trimmed.
The largest buyer was Barclays, adding an estimated $47.1M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $783M sold.
- 99 institutional investors held Indivior Pharmaceuticals (INDV) as of Q2 2024, up from 95 in Q1 2024.
- Funds reported $1.22B of Indivior Pharmaceuticals stock for Q2 2024, down 64% quarter-over-quarter.
- 19 funds opened new Indivior Pharmaceuticals positions in Q2 2024 and 14 closed out, a net change of +5 holders.
- The largest Indivior Pharmaceuticals buyer in Q2 2024 was Barclays, an estimated $47.1M added.
- The largest Indivior Pharmaceuticals seller in Q2 2024 was Polar Capital Holdings, an estimated $783M sold.
Based on aggregated 13F filings for Q2 2024.